Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26768653 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8566031 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5342329 | 0.87 | SMN1; SMN2 (0.84) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6490238 | 0.86 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL3816798 | 0.86 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6492074 | 0.84 | ALDH1A1 (0.61) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2559289 | 0.84 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5155116 | 0.84 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29853676 | 0.84 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7267474 | 0.84 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ECYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-0598702-B1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | EISAI CO LTD (JP) | 1998-06-10 | — | — | EP | disclosed |
| EP-0628557-B1 | Biphenylmethane derivatives, the use of them and pharmacological compositions containing same | EISAI CO LTD (JP) | 1997-05-02 | — | — | EP | disclosed |
| US-5506238-A | HYPOTENSIVE AGENT | EISAI CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0420237-B1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | EISAI CO LTD (JP) | 1996-03-06 | — | — | EP | disclosed |
| EP-0628557-A1 | Biphenylmethane derivatives, the use of them and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1994-12-14 | — | — | EP | disclosed |
| US-5328911-A | Cardiovascular disorders, hypotensive agents and congestive heart failure | EISAI CO., LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| EP-0598702-A1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-5298518-A | Biphenylmethane derivative and pharmacological use | EISAI CO., LTD. (JP) | 1994-03-29 | — | — | US | disclosed |
| EP-0420237-A1 | Biphenylmethane derivative, the use of it and pharmacological compositions containing same | Eisai Co., Ltd. (JP) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMN1; SMN2 1921/4885KDM4E 2286/4885CYP1A2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.